Abstract: Methods and formulations of modified release amino acids are provided for the treatment or management of diseases defined by impaired amino acid metabolism, with improved pharmacokinetics, metabolism and utilization.

Abstract: The present invention relates to a liquid cosmetic composition comprising, in a physiologically acceptable medium: at least 20% of water, at least alkylcellulose, preferably at least 1% of alkylcellulose, at least one first hydrocarbon-based non-volatile oil, chosen from: C10-C26 alcohols, preferably monoalcohols; optionally hydroxylated monoesters, diesters or triesters of a C2-C8 monocarboxylic or polycarboxylic acid and of a C2-C8 alcohol; esters of a C2-C8 polyol and of one or more C2-C8 carboxylic acids, at least one second non-volatile oil chosen from silicone oils and/or fluoro oils; at least one third oil, the said third oil being chosen from hydrocarbon-based oils other than the said first oil; at least one surfactant, preferably non-ionic.

Abstract: The invention relates to inhalable imatinib formulations, manufacture, and uses thereof.

Abstract: A pellet contains a core, which contains one or more biologically active ingredients, and a coating layer on the core. The coating layer contains a mixture of a first polymer and a second polymer. The first polymer is a core-shell polymer, containing 50 to 90% by weight of a core, containing polymerized units of 60 to 85% by weight of ethyl acrylate and 20 to 40% by weight of methyl methacrylate; and 10 to 50% by weight of a shell, containing polymerized units of 40 to 60% by weight ethyl acrylate and 40 to 60% by weight methacrylic acid. The second polymer contains polymerized units of 40 to 60% by weight of methacrylic acid and 60 to 40% by weight of ethyl acrylate or methyl methacrylate. A Multi-Unit Pellet System (MUPS), preferably a compressed tablet, contains a multitude of the pellets.

Abstract: The invention relates to a lozenge comprising micronized benzocaine, at least one dissolution enhancer and one or more excipients as well as the use of the lozenge for the treatment of sore throat.

Abstract: Provided herein are transdermal delivery devices comprising dextromethorphan. The transdermal delivery device can be characterized by the novel design, for example, with an adhesive layer and a reservoir layer, with an adhesive layer comprising a mixture of two adhesives, and/or with a skin permeation enhancer, e.g., in an amount that can significantly enhance the flux of dextromethorphan. The transdermal delivery device can also be characterized by its in vitro and/or in vivo release profile, for example, that can provide a desired pharmacokinetic profile described herein. Also provided herein are methods of administering dextromethorphan, and methods of treating a disease or disorder described herein, using the transdermal delivery device herein.

Abstract: The invention disclosed herein relates to novel synergistic medicinal compositions for treating dysfunctional D-serine (DSR) signaling. Particularly the invention provides potent synergistic medicinal composition comprising combination of N-acetyl taurinate salt of divalent metal (M2+AT) as serine racemase enzyme (SR) activator/stimulator and benzoic acid ester salt of monovalent or divalent metals (M+/2+Bz) as d-amino acid oxidase enzyme (DAAO) inhibitor, which are present in weight ratio of 1:0.001 to 1:1.5 along with pharmaceutically acceptable excipients. Further the present synergistic medicinal composition is useful for treating certain neuropsychiatric disorders, neurological disorders and metabolic disorders.

Abstract: A patch comprising: a backing layer; and an adhesive layer, wherein the adhesive layer contains a mixture of a pharmaceutically acceptable acid addition salt of ropinirole and potassium hydrogen carbonate, and the mixture contains at least one selected from the group consisting of ropinirole and pharmaceutically acceptable acid addition salts thereof and potassium hydrogen carbonate.

Abstract: A composition for reducing or preventing development of one or more symptoms of alcohol consumption includes at least prickly pear extract, reduced L-Glutathione, N-Acetyl-L-Cysteine (NAC), licorice root extract, and milk thistle, which are present in the composition in effective amounts sufficient in combination to reduce or prevent development of one or more detrimental symptoms of alcohol consumption. Also disclosed are methods of reducing or prevent the development of detrimental symptoms of alcohol consumption using the compositions.

Abstract: A synergistic disinfectant composition comprises a C1-8 organic acid, an amino acid based surfactant, an anionic surfactant, and a stabilizing agent. The C1-8 organic acid may include two or more types of the C1-8 organic acids with at least one of the C1-8 organic acids is alpha hydroxyl acid. The disinfectant composition has an antimicrobial activity of log reduction of at least 2 under Biocidal Product Registration (BPR) standard EN13727, EN1276, EN13624 or EN1499, and/or the EPA standard that applies the “Quantitative Methods for Evaluating the Activity of Microbicides used on Hard, Non-Porous Surface” issued by the Organisation for Economic Co-operation and Development (OECD). In addition, the disinfectant composition may be stable during storage and retain their antimicrobial activity after at least one month at 40° C. When desired, the synergistic disinfectant composition may further comprise an oxidizing agent.

Abstract: Disclosed are various embodiments of lipid multiparticulate compositions comprising at least one active agent, a low flow point excipient, and a high flow point excipient.

Abstract: A composition, especially a cosmetic composition, for making up and/or caring for keratin materials, in particular the skin and/or the lips, and keratin fibres, especially the eyebrows, comprising at least one aqueous phase gelled with at least one hydrophilic gelling agent, and at least one oily phase gelled with at least one lipophilic gelling agent, said phases forming therein a macroscopically homogeneous mixture and said composition also comprising at least one hydrophobic film-forming polymer.

Abstract: The potential for substance abuse involving residual amounts of abusable substances remaining in used skin-worn patches is reduced by the provision of a system and method for combining the abusable substance with a separate anti-abuse substance agent as part of a removal or disposal procedure.

Abstract: The invention relates to inhalable imatinib formulations, manufacture, and uses thereof.

Abstract: An edaravone suspension for human oral administration includes edaravone particles, a dispersant, and water.

Abstract: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.

Abstract: The present invention relates to a topical composition (and methods of producing the such compositions) for the treatment of a fungal infection comprising a polymer capable of forming nanoparticles and an antifungal agent. The invention also relates to novel uses of polyhexamethylene biguanide.

Abstract: Nanoparticle based MKT formulation. MKT is encapsulated by poly(ethylene glycol)ylated (PEGylated) poly-(lactide-co-glycolide) (PLGA) to form nanoparticles (NPs). To induce trans-BBB permeability, glutathione (GSH) is coated on the resulting NPs. Newly generated MKT-NPs showed BBB permeability and tau reduction in experimental models. Specifically, brain-targeting MKT NPs were developed with a glutathione coating, characterized, and shown to permeate BBB permeation insert models as a therapeutic for Alzheimer's disease and related tauopathies.

Abstract: A method for production of an additive case having the steps of preparing a zinc oxide concentration from a paste of nanometric zinc oxide that was previously subjected to surface treatment based on silane additives, preparing a silver concentrate starting from a silver paste of nanometric metallic silver, and preparing the additive paste by mixing the zinc oxide concentrate and the silver concentrate and a polymeric carrier with a compatible resin. The polymeric carrier and compatible resin are in a proportion of between 10:90 to 90:10. The steps obtains the additive paste of ZnO/AG° in masterbatch in pellet form.

Abstract: The invention provides amphiphilic liquid crystalline brush block copolymers that can readily self-assemble to nanoparticles in aqueous solutions and also allow for encapsulation of hydrophobic pharmaceutically active molecules.